New Hampshire Medicaid Fee-for-Service Program

Direct Renin Inhibitor and Combination Criteria

Approval Date: August 7, 2020

Pharmacology

Aliskiren is a direct renin inhibitor, hydrochlorothiazide is a thiazide diuretic, valsartan is an angiotensin receptor blocker (ARB), and amlodipine is a calcium channel blocker.

Medications

Brand Names	Generic Names	Dosage
Amturnide®	aliskiren, amlodipine, and hydrochlorothiazide	150/5/12.5 mg, 300/5/12.5 mg, 300/10/12.5 mg, 300/5/25 mg, 300/10/25 mg
Tekamlo®	aliskiren and amlodipine	150/5 mg, 150/10 mg, 300/5 mg, 300/10 mg
Tekturna®	aliskiren	150 mg, 300 mg unscored tablets
Tekturna HCT®	aliskiren and hydrochlorothiazide	150/12.5 mg, 150 mg/25 mg, 300/12.5 mg, 300/25 mg

Criteria for Approval

1. Patient has a diagnosis of hypertension; **AND**
2. Patient is ≥18 years old; **AND**
3. Patient is not pregnant; **AND**
4. Allergy, contraindication, or history of unacceptable/toxic side effects to all medications not requiring prior approval; **OR**
5. Evidence of a seven-day trial or failure of **ONE** medication in **EACH** of the following classes of medications:
   a. ACE inhibitors and/or ACE combinations
   b. Angiotensin Receptor Antagonist and/or ARB combinations

Length of Approval: One year.

Proprietary & Confidential
© 2003–2020 Magellan Health, Inc. All rights reserved.
Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc.

Criteria for Denial

1. Prior authorization will be denied if the approval criteria are not met; **OR**
2. No evidence of prior trials of ACE inhibitors and/or ACE combinations and Angiotensin Receptor Antagonist and/or ARB combinations; **OR**
3. Pregnancy; **OR**
4. Patient is ≤ 17 years old; **OR**
5. Patient will be on concurrent therapy of ACE inhibitors or ARBs and a direct renin inhibitor/combination with renal impairment of GFR < 60 mL/min; **OR**
6. Patient has a diagnosis of diabetes.

References

Available upon request.

Revision History

Reviewed by	Reason for Review	Date Approved
Pharmacy & Therapeutic Committee	New	10/25/2007
Commissioner	Approval	11/20/2007
Pharmacy & Therapeutic Committee	Update	11/06/2008
Commissioner	Approval	12/01/2008
DUR Board	Revision	03/22/2010
Commissioner	Approval	04/30/2010
DUR Board	Revision	06/15/2011
Commissioner	Approval	09/29/2011
DUR Board	Revision	06/18/2012
Commissioner	Approval	07/10/2012
DUR Board	Revision	03/20/2017
Commissioner	Approval	06/08/2017
DUR Board	Revision	03/12/2019
Commissioner Designee	Approval	04/05/2019
DUR Board	Revision	06/30/2020
Commissioner Designee	Approval	08/07/2020